Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimer's & Parkinson's Diseases

CALGARY, Alberta, April 01, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announces that Dr. Jeffrey Cummings, Founding Director of the Cleveland Clinic Lou Ruvo Brain Health Center, Las Vegas, Nevada, gave an oral presentation this past weekend at the 14th International Conference on Alzheimer's & Parkinson's Diseases (AD/PD) held in Lisbon, Portugal, titled: *Cognitive Evaluation of Treatment Effects of the Bromodomain Inhibitor Apabetalone: Baseline Data of the Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial.* The presentation can be viewed on the Company's website by accessing the following LINK.

During the presentation, Dr. Cummings discussed certain risk factors – including diabetes, coronary heart disease and heart failure – associated with an increased risk of cognitive decline, cognitive impairment or dementia. Furthermore, Dr. Cummings delivered the hypothesis that dementia risk in diabetes and cardiovascular disease patients is caused by transcriptional disturbances at the epigenetic level.

The presentation also highlighted the potential of the Company's small molecule – apabetalone, a selective bromodomain and extra-terminal inhibitor – to regulate disease-associated genes, proteins and pathways related to neuroinflammation and neurodegeneration, the BETonMACE study design, the cognition subgroup study methods and patient baseline characteristics.

The BETonMACE trial is currently expected to be completed within the first half of calendar 2019. The study is an event-based trial and will continue until at least 250 major adverse cardiac events (MACE), defined as cardiovascular death, non-fatal myocardial infarction and stroke, have occurred. Third party adjudication of all MACE events are anticipated to be available within two to three months past trial completion. The topline results of the study will be made available shortly thereafter.

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us on Twitter: @Resverlogix_RVX

For further information please contact:

Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the timing of the Company's Phase 3 clinical trial and the potential role of apabetalone in the treatment of high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.